A Role for cAMP-Driven Transactivation of EGFR in Cancer Aggressiveness – Therapeutic Implications

A signaling molecule known as cyclic AMP (cAMP) is produced in many cancers, and makes them more aggressive. Adrenergic hormones (adrenaline, noradrenaline), as well as hormones produced by the pro-inflammatory cox-2 enzyme, boost cAMP production in many cancers. Hence, drugs which block cox-2 activity, or which inhibit receptors for adrenergic hormones, may have potential for cancer prevention and control. Drugs known as beta-blockers inhibit the activity of adrenergic hormones, and some studies show that cancer patients taking certain forms of these drugs have improved survival. Hence, beta-blockers may have a future as adjuvant therapies for cancer, and might also reduce cancer risk.

Click to download